Vascular Pharmaceuticals Adds $9M in Series A Funding
March 05, 2015
Vascular Pharmaceuticals (VPI), a clinical stage company addressing the complications of diabetes, has increased its Series A financing with a $9 million expansion, bringing the round total to $25 million. Lead investor Lumira Capital was joined by existing investors including Intersouth Partners and MPM Capital; Lumira's Beni Rovinski will join the company's Board of Directors. VPI plans to use the proceeds to fund the ongoing Phase 2 clinical trials of VPI-2690B for the treatment of diabetic nephropathy.